tuberculosis - PRWeb Press Release Group

Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges

Sat, 02 Feb 2013 10:25:00 GMT

Ukrainian Ekomed company's Immunoxel formulated into Honey Lozenges™ has been awarded Global Science & Technology Entrepreneurship Program grant from the Civilian Research & Development Foundation (CRDF). The funding will go toward clinical trial and marketing effort of honey-formulated herbal supplement, shown effective as an immune adjunct against tuberculosis.

(PRWeb February 02, 2013)

Read the full story at http://www.prweb.com/releases/2013/2/prweb10382670.htm

High Success Rate in Immunotherapy Trial of TB/HIV 'Deadly Duo' Infection

Sun, 19 Jul 2009 07:01:00 GMT

Adjunct immunotherapy with herbal supplement Immunoxel (Dzherelo) combined with first-line TB drugs resulted in clearance of Mycobacterium tuberculosis in sputum cultures: 67% vs. 16% patients treated with TB drugs alone, with average time to negative culture 4 and 6 months respectively. Immunoxel, given at 50 drops twice-per-day dose, resulted in higher healing rate of cavitary/miliary involvements - i.e. 60%/84% in Immunoxel patients and 25%/46% in ATT alone patients. Immunotherapeutic intervention produced significant positive changes in body weight: 5.8±2.6 kg gain vs. 0.6±2.4 kg loss in ATT only patients. The incidence of opportunistic infections reduced in ATT + Immunoxel patients - 3 episodes vs. 12 episodes in ATT alone patients. This study appeared in British journal Immunotherapy (July 2009, Vol. 1, No. 4, Pages 549-556 - see link to the abstract at - http://www.futuremedicine.com/doi/abs/10.2217/imt.09.25

(PRWeb July 19, 2009)

Read the full story at http://www.prweb.com/releases/2009/07/prweb2653584.htm

Faster TB Healing by Combining Dzherelo (Immunoxel) with TB Drugs

Fri, 29 May 2009 07:01:00 GMT

The clinical study in 75 first-diagnosed TB patients published in the monthly journal of journal of the European Society of Clinical Microbiology and Infectious Diseases reveals that when standard, first-line TB drugs are combined with Dzherelo (Imunoxel), the combination can produce significant clinical and radiological improvements and clearance of M. tuberculosis at higher rate than in patients on TB drugs alone. Biochemistry and hematological analysis of blood samples support favorable adjunctive effect of Dzherelo, which has not shown any adverse effects throughout the study duration.

(PRWeb May 29, 2009)

Read the full story at http://www.prweb.com/releases/2009/05/prweb2470834.htm

Ekomed presents at the 5th Congress of the International Union Against Tuberculosis and Lung Disease

Thu, 28 May 2009 07:01:00 GMT

Promising findings from Ukrainian XDR-TB immunotherapy trial will be presented at the 5th conference of the International Union Against Tuberculosis and Lung Disease (The Union), Europe Region, held in Dubrovnik, Croatia, between 27 and 30 May 2009. During conference all fields of tuberculosis and respiratory medicine will be covered by world renowned experts. The Immunoxel clinical study demonstrated the drastic difference between standard TB drugs alone versus TB drugs supplemented with immune adjuvant regimen consisting of Ekomed phytoconcentrates.

(PRWeb May 28, 2009)

Read the full story at http://www.prweb.com/releases/2009/05/prweb2465964.htm

Sales of Ekomed Botanical Immunomodulator Started in Asia

Thu, 23 Apr 2009 07:01:00 GMT

Ekomed LLC announces that it has sold and shipped the first order of its phyto-concentrate Dzherelo (Immunoxel) for sale outside the Ukraine. This first shipment of 5,000 units was delivered to Mongolia - one of the highest TB burden countries in Western Pacific region and a second order for 10,000 units has already been received.

(PRWeb April 23, 2009)

Read the full story at http://www.prweb.com/releases/2009/04/prweb2345154.htm